Iron accumulation and tau protein deposition are pathological features of Alzheimer's (AD) and Parkinson's diseases (PD). Soluble tau protein is lower in affected regions of these diseases, and we previously reported that tau knockout mice display motor and cognitive behavioral abnormities, brain atrophy, neuronal death in substantia nigra, and iron accumulation in the brain that all emerged between 6 and 12 months of age. This argues for a loss of tau function in AD and PD. We also showed that treatment with the moderate iron chelator, clioquinol (CQ) restored iron levels and prevented neuronal atrophy and attendant behavioral decline in 12-month old tau KO mice when commenced prior to the onset of deterioration (6 months). However, therapies for AD and PD will need to treat the disease once it is already manifest. So, in the current study, we tested whether CQ could also rescue the phenotype of mice with a developed phenotype. We found that 5-month treatment of symptomatic (13 months old) tau KO mice with CQ increased nigral tyrosine hydroxylase phosphorylation (which induces activity) and reversed the motor deficits. Treatment also reversed cognitive deficits and raised BDNF levels in the hippocampus, which was accompanied by attenuated brain atrophy, and reduced iron content in the brain. These data raise the possibility that lowering brain iron levels in symptomatic patients could reverse neuronal atrophy and improve brain function, possibly by elevating neurotrophins.
Introduction
Alzheimer's disease (AD) and Parkinson's disease (PD) are both agedependent chronic neurological disorders, which pathologically feature protein aggregation and iron accumulation in the affected brain regions (Hare et al., 2013; Ayton et al., 2015a) . Despite significant efforts made in the last two decades, there is still no disease modifying treatment for either disease. Most recently, a number of large Phase III clinical trials targeting β-amyloid aggregation, a key feature of AD, were conducted, but failed to demonstrate efficiency (Doody et al., 2013 (Doody et al., , 2014 Salloway et al., 2014) . It is therefore of crucial importance to search for alternative drug targets that may modify the disease symptoms.
Tau protein is extensively implicated in the pathogenesis of AD and considered as a potential drug target (Gozes, 2010) . Recent genomewide association studies identified a significant association between the MAPT locus and sporadic PD (Lei et al., 2010; Nalls et al., 2014) , indicating a possible pathological link between tau and PD. The link was supported by pathological findings including the interaction between α-synuclein and tau, and the presence of tau in the Lewy bodies of typical PD (Lei et al., 2010; Arima et al., 1999) . Furthermore, tau mutations cause atypical PD syndromes, such as progressive supranuclear palsy, and corticobasal degeneration (Gozes, 2010) . While the hyperphosphorylation of tau causes toxicity (Morris et al., 2011), increasing evidence also supports a possible role for functional loss of tau protein in both diseases, as soluble tau is reduced in the affected regions in both disorders (Lei et al., 2012; Kosik et al., 1989; Zhukareva et al., 2001) . We previously reported that tau knockout mouse display progressive motor and cognitive behavioral abnormalities, brain weight loss and brain-wide atrophy, loss of key proteins involved in memory formation, neuronal death in substantia nigra (SN), dopamine loss and tyrosine hydroxylase (TH) terminal loss in the caudate-putamen (CPu), as well as iron accumulation in the brain; all of which are features of neurodegeneration (Lei et al., 2012 (Lei et al., , 2014 . Others showed that tau knockout mice (on a different genetic background) display progressive motor and cognitive deficits, in association with a loss of microtubule associated proteins other than tau, and the phenotypes can be prevented by an anti-oxidant (Ma et al., 2014) . Although the cognitive phenotypes of tau knockout mouse may depend on its genetic background and food (Gheyara et al., 2014; Morris et al., 2013) , the tau knockout mouse remains to be a useful model of agedassociated neurodegeneration which can be utilized for drug discovery. 
